NASDAQ:TIL Instil Bio Q4 2025 Earnings Results & Report $6.18 -0.06 (-0.93%) As of 12:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Instil Bio beat analyst earnings expectations in its Q4 2025 results, released March 27, 2026. The company reported EPS of -$1.21 versus the -$2.31 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 27, 2026TimeBefore Market Opens Instil Bio EPS ResultsActual EPS-$1.21Consensus EPS -$2.31Beat/MissBeat by +$1.10One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersInstil Bio Revenue ResultsActual RevenueN/AExpected Revenue$1.90 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsInstil Bio's next earnings date is estimated for Monday, November 16, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Instil Bio Q4 2025 Earnings FAQ Did Instil Bio beat earnings estimates for Q4 2025? Instil Bio (NASDAQ:TIL) reported earnings of -$1.21 per share for Q4 2025, beating the consensus estimate of -$2.31. The report was announced on Friday, March 27, 2026. When is Instil Bio's next earnings date? Instil Bio's next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for Instil Bio on the company's earnings history page. Instil Bio Earnings HeadlinesInstil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 13, 2026 | globenewswire.comIovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)July 16, 2026 | seekingalpha.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 13 at 1:00 AM | Behind the Markets (Ad)Instil Bio Shareholders Back Directors and Auditor at MeetingJune 11, 2026 | tipranks.comInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comInstil Bio (TIL) Price Target Increased by 24.53% to 67.32April 9, 2026 | msn.comSee More Instil Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email. Email Address About Instil BioInstil Bio (NASDAQ:TIL) is a clinical-stage biotechnology company focused on developing novel T-cell therapies for the treatment of cancer. The company’s research centers on tumor-infiltrating lymphocytes (TILs), immune cells that can recognize and attack cancer cells within tumors. Instil Bio is developing engineered TIL programs intended to improve the ability of these cells to persist, function, and target solid tumors. Its pipeline has included investigational therapies such as ITIL-306, an engineered TIL product designed to target CD70-expressing cancers, along with other early-stage cell therapy candidates. The company was founded in 2015 and became a publicly traded company in 2021. Instil Bio is headquartered in Dallas, Texas, and conducts research and development through its biotechnology operations. Its therapies remain investigational and are subject to clinical and regulatory evaluation.View Instil Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
